Announcement • Jul 07

Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd

cbdMD, Inc. announced the completion of a self-affirmed Generally Recognized as Safe (GRAS) determination supporting the safe consumption of up to 200 mg per day of cannabidiol (CBD), as delivered in the Company's proprietary broad spectrum hemp extract, in healthy adults, addressing one of the most common questions in the category of how much CBD is safe to consume per day. The self-affirmed GRAS determination represents the culmination of years of scientific investment by cbdMD to establish a comprehensive body of evidence supporting the safety of its broad spectrum CBD products. Over the past several years, the Company has worked to develop a substantial dossier of safety data, including studies conducted in rodents, healthy human volunteers, and canines, designed to characterize the safety profile of its broad spectrum CBD formulations. This research has been published in the peer-reviewed scientific literature, spanning toxicology, genotoxicity, human tolerability, and companion-animal studies, a depth of published evidence that distinguishes cbdMD within the hemp-derived CBD category. This extensive body of evidence was assembled through a rigorous scientific program that evaluated multiple aspects of safety across relevant preclinical and clinical models. The resulting safety dossier forms the foundation of the Company's self-affirmed GRAS conclusion, which supports the intended use of cbdMD's broad spectrum CBD products at a daily intake of up to 200 mg for healthy adults. The determination was made by an independent panel of expert toxicologists following a review of the available scientific literature on the safety of cannabidiol. In 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive, a first-of-its-kind initiative under which participating care organizations may offer eligible patients physician-guided access to non-intoxicating, third-party-tested hemp-derived CBD, and the U.S. Food and Drug Administration signaled enforcement discretion for orally administered CBD products meeting dietary-supplement standards in that context. The safety substantiation also supports cbdMD's ability to develop and position products across a range of formats and use occasions, from daily wellness to targeted active-lifestyle and recovery applications, and to serve both direct-to-consumer and healthcare-oriented channels. By establishing a science-backed daily intake ceiling, the determination gives clinicians, retail partners, and consumers a clear reference point for confident, consistent use across the Company's broad spectrum product line. cbdMD's contributions to the peer-reviewed scientific literature on cannabinoid safety span several study types and species. They include subchronic oral toxicity and genotoxicity assessments of the Company's cannabis extract; pharmacokinetic and tissue-accumulation research; a double-blind, randomized controlled trial of tolerability in healthy adults; and a double-blind, placebo-controlled study in dogs. These studies were sponsored by cbdMD, Inc. and were conducted in collaboration with independent research organizations, academic investigators, and accredited laboratories.

cbdMD, Inc. Stock Price

YCBD Share Price Performance

YCBD Community Narratives

Hemp-Derived CBD And Functional Beverages Will Drive Long-Term Market Share Gains

Hemp-Derived CBD And Functional Beverages Will Drive Long-Term Market Share Gains

Trending Discussion

Recently Updated Narratives

Hemp-Derived CBD And Functional Beverages Will Drive Long-Term Market Share Gains

Snowflake Analysis

cbdMD, Inc. Key Details

About YCBD

Recent YCBD News & Updates

Third quarter 2026 earnings: EPS and revenues miss analyst expectations

cbdMD, Inc. to Report Q3, 2026 Results on Aug 13, 2026

Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd

Recent updates

cbdMD, Inc. Competitors

Regentis Biomaterials

Quoin Pharmaceuticals

Aspire Biopharma Holdings

Lunai Bioworks